UCB SA continued to invest significant sums in research and development in 2022 even as group revenue declined under the weight of patent expires. The Belgian-based company saw a 4% decline in revenue to €5.5 billion from a year earlier largely due to the loss of exclusivity for the epilepsy drugs Vimpat and Keppra. At the same time, the company maintained a high level of investment, spending 30% of revenue on new product development during the year, up from 28% in 2021.
